ArQule 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 18, 2012
(Exact Name of Issuer as Specified in Charter)
19 Presidential Way
(Address of principal executive offices)
(Registrant's telephone number, including area code)
Section 8 — Other Events
Item 8.01 Other Events.
On May 18, 2012, ArQule, Inc. (the “Registrant”) announced that recruitment of patients has been completed in the randomized, double-blind, controlled Phase 3 MARQUEE pivotal trial of its investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. Phase 2 and Phase 3 clinical development of tivantinib is being carried out by the Registrant and its development and commercialization partner, Daiichi Sankyo, Co., Ltd.
The Registrant’s press release dated May 18, 2012, a copy of which is attached hereto as Exhibit 99.1, is incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
May 18, 2012